Dueling for Duals: Why the Poorest Medicare Recipients Should be Pharma's Top Priority in 2006
This article was originally published in RPM Report
Executive Summary
The transfer of the poorest Medicare recipients to Part D means big changes in a critical submarket for pharma. If all goes well, it should pay off in a de facto price increase for some of the biggest industry blockbusters.
You may also be interested in...
Pfizer's Lipitor Sees Big Boost From Medicare
Pfizer is discounting its blockbuster brand Lipitor more aggressively. But, thanks to the economics of Medicare Part D, the product is still benefiting from a big net price increase in 2006. Lipitor's performance is some much needed good news for Pfizer--and maybe even better news for the industry as a whole.
Medicare Market Share: Drug Plan Starts With Big Four
Pharmaceutical manufacturers interested in maximizing their market share under the new Medicare drug benefit in 2006 should focus on four insurers likely to take the lion's share of enrollment. Dozens of plans are entering the market, but UnitedHealth Group, Wellpoint, Humana and Wellcare will start with a big edge in enrollment as of January 1. An analysis by The RPM Report explains why.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.